没有数据	没有数据

没有数据	没有数据

来源	SDS样本
Matrix	浏览或下载

产品合成路线

更多

名称	CAS号

更多

文章

同行评议文献

Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.Zana Stanković et al.Vojnosanitetski pregled, 70(3), 267-273 (2013-04-24) The challenge of patients with severe psychiatric illness who do not access care - a way forward.Sushil Mathew John et al.Tropical doctor, 40(4), 247-248 (2010-09-10) Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.Trino Baptista et al.Schizophrenia research, 89(1-3), 350-352 (2006-10-13) Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.Leslie Citrome et al.Schizophrenia research, 119(1-3), 153-159 (2010-03-30) Switching as only temporal solution for patients with antipsychotic-associated diabetes: further observations.Branimir Margetić et al.Psychiatria Danubina, 19(1-2), 87-88 (2007-07-03) Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.Elizabeth B Stuyt et al.The American journal on addictions, 15(2), 166-173 (2006-04-06) Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.N Kirk Morton et al.Journal of psychosocial nursing and mental health services, 51(3), 13-18 (2013-04-03) Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.S R Marder et al.Schizophrenia research, 53(1-2), 25-30 (2001-12-01) Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.Lizheng Shi et al.Psychiatric services (Washington, D.C.), 58(4), 482-488 (2007-04-07) Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.Pang-Yen Liu et al.General hospital psychiatry, 33(1), 84-84 (2011-03-01) Who receives long-acting antipsychotic medications?William M Glazer Psychiatric services (Washington, D.C.), 58(4), 437-437 (2007-04-07) Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.Takahito Uchida et al.International clinical psychopharmacology, 28(5), 261-266 (2013-07-04) Clozapine and tardive dyskinesia.Del D Miller The American journal of psychiatry, 160(3), 588-588 (2003-03-04) Rehospitalization risk with second-generation and depot antipsychotics.Robert R Conley et al.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 15(1), 23-31 (2003-07-04) Importance of oral glucose tolerance test in patient with schizophrenia.Branimir Margetić et al.Psychiatria Danubina, 17(1-2), 94-96 (2006-01-07) Adverse extrapyramidal effects in four horse given fluphenazine decanoate.John D Baird et al.Journal of the American Veterinary Medical Association, 229(1), 104-110 (2006-07-05) Use of aripiprazole in tardive dyskinesia: an open label study of six cases.Rajaprabhakaran Rajarethinam et al.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 10(4 Pt 2), 416-419 (2009-06-06) Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia.George Bartzokis et al.Schizophrenia research, 93(1-3), 13-22 (2007-04-05) Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.S E McCormick et al.Neuroscience, 119(2), 547-555 (2003-05-29) Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.Martin Turner et al.International clinical psychopharmacology, 19(4), 241-249 (2004-06-18) Risks versus benefits of different types of long-acting injectable antipsychotics.Joseph P McEvoy The Journal of clinical psychiatry, 67 Suppl 5, 15-18 (2006-07-11) Management of psychosis in Australian general practice.Janice Charles et al.Australian family physician, 35(3), 88-89 (2006-03-10) Mis-deca-n identity?Elizabeth A S Giugni et al.The Medical journal of Australia, 187(6), 370-370 (2007-09-19) Flow and injection characteristics of pharmaceutical parenteral formulations using a micro-capillary rheometer.Ayman Allahham et al.International journal of pharmaceutics, 270(1-2), 139-148 (2004-01-17) Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.Zana Stanković et al.Psychiatria Danubina, 20(1), 42-52 (2008-04-01) The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.David C Mamo et al.International journal of geriatric psychiatry, 17(11), 1012-1017 (2002-10-31)

备注